Silo Pharma Advances PTSD Treatment with Innovative Nasal Spray System

Silo Pharma (NASDAQ: SILO) has entered into a service agreement with Resyca BV to conduct a critical drug-device study on its microchip-enabled nasal spray system, a key component of its lead PTSD treatment candidate, SPC-15. This study aims to gather the final device data required for an Investigational New Drug (IND) application to the FDA, anticipated later this year. The innovative device's capability to bypass the blood-brain barrier could revolutionize therapeutic delivery, offering a faster and safer alternative for patients suffering from PTSD and stress-induced anxiety disorders.

Under the leadership of CEO Eric Weisblum, Silo Pharma is not only focusing on the nasal spray system but is also advancing two additional SPC-15 studies. These include a GLP-compliant toxicology study and a 7-day large animal safety trial, both requested by the FDA. These efforts underscore Silo Pharma's commitment to addressing underserved conditions through novel therapeutics and drug-delivery systems.

Silo Pharma's portfolio extends beyond SPC-15, with SP-26, a time-release, ketamine-loaded implant for fibromyalgia and chronic pain relief, and two preclinical programs: SPC-14, targeting Alzheimer’s disease, and SPU-16, aimed at multiple sclerosis. The company's collaborative approach with universities and independent laboratories emphasizes its dedication to innovation in the biopharmaceutical sector.

The implications of Silo Pharma's advancements are significant, not only for the company but for the broader cannabis and psychedelic industries. By pushing the boundaries of drug delivery and treatment options, Silo Pharma is contributing to the growing body of research that could transform mental health and chronic pain management. The potential FDA approval of SPC-15 could pave the way for new standards in therapeutic delivery, offering hope to millions affected by PTSD and related conditions.